Clinical Research

Sumitomo Pharma Co. Ltd.

Address
6-8 Doshomachi 2 Chome, Chuo Ku

Sponsor Overview

assignment
2
sponsored trials
science
1
molecule
location_city
5
research centres
public
2
countries
person_search
6
investigators

Specializations

Psychiatry and Schizophrenia

Clinical research in acutely psychotic schizophrenia focuses on symptom control, with attention to positive and negative syndrome burden and overall psychiatric stabilization.

  • Schizophrenia
  • Acute psychosis
  • PANSS symptom assessment

The sponsor’s activity in this area reflects interest in treatments for severe mental health conditions requiring rapid clinical management.

Infectious Disease and Influenza Prevention

Research in influenza centers on vaccine-based strategies, including work relevant to broader viral respiratory protection and immune response generation.

  • Influenza
  • Vaccine immunogenicity
  • Respiratory virus prevention

This area includes interest in enhancing protection against seasonal and potentially broader influenza strains through immunization research.

Central Nervous System Therapeutics

The sponsor’s neuropsychiatric portfolio includes therapies aimed at severe disturbances of thought, perception, and behavior within the central nervous system.

  • Neuropsychiatry
  • Psychotic disorders
  • Behavioral symptom management

Clinical interest in this domain is directed toward treatment options for patients with marked psychiatric symptom severity.

Immunology and Vaccine Development

Vaccine-focused research emphasizes immune response assessment and protective antigen design for infectious disease prevention.

  • Adjuvanted vaccines
  • Immunogenicity
  • Healthy adult vaccine evaluation

These studies place the sponsor within areas of preventive medicine that depend on improving immune recognition and tolerance.

Sponsored Trials

Trial Name Country Status
Efficacy and Safety Evaluation of Ulotaront (SEP-363856) in Acutely Psychotic Schizophrenia Patients: A Randomized, Double-Blind, Placebo-Controlled StudyRomania RomaniaNot Recruiting
Phase 1 Study on Safety, Tolerability, and Immunogenicity of Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LP in Healthy AdultsBelgium BelgiumNot Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
0
Exclusive Molecules
out of 1 total (0% not shared with other sponsors)

This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
0%
Return partnership rate
0 of 5 sites collaborated multiple times

This sponsor has worked with 5 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Mental Disorders1 trial
    150 other sponsors
  • 2.
    Virus Diseases1 trial
    182 other sponsors

Partnered Research Centres

5 centres
location_city
assignment16
Centru De Evaluare Si Tratament A Toxicodependentelor Pentru Tineri Sf. Stelian
Address
Strada Ing Cristian Pascal 25-27 Sector 6, 060222 Bucharest
Learn morearrow_forward
location_city
assignment20
Institutul De Psihiatrie Socola Lasi
Address
Soseaua Bucium 36, 700282 Iasi
Learn morearrow_forward
location_city
assignment41
Spitalul Clinic De Psihiatrie Prof.Dr.Alexandru Obregia
Address
Strada Argeselu Nr 8, 040874 Bucharest
Learn morearrow_forward
location_city
assignment17
Spitalul Clinic De Psihiatrie Si Neurologie Brasov
Address
Strada Prundului 7-9, 500123 Brasov
Learn morearrow_forward
location_city
assignment811
Universitair Ziekenhuis Gent
Address
Corneel Heymanslaan 10, 9000 Ghent
Learn morearrow_forward

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Sumitomo Pharma Co. Ltd..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.